Skip to main content
Premium Trial:

Request an Annual Quote

CombiChem Appoints Two Scientists to Research Management Positions

Premium

SAN DIEGO--CombiChem, a computational drug discovery company here, has named two scientists to management positions. Klaus Gubernator was appointed vice-president of special projects, and Robert Zambias will be director of chemistry automation. The two are both members of a technology research group led by Steven Teig, CombiChem's vice-president for advanced technology.

Gubernator formerly directed the molecular design and bioinformatics section in pharmaceutical preclinical research at Hoffman-LaRoche's research facility in Basel. Among other things, he led the development and application of structure-based design and bioinformatics technologies there. Zambias was previously at ArQule, where he served as executive director of automated synthesis, leading the design, construction, and implementation of the company's automated chemistry program and forming the company's Automated Synthesis Engineering and Chemistry Groups.

CombiChem uses its proprietary Discovery Engine process to focus on the generation, evolution, and optimization of potential new lead candidates for its collaborative partners, who include Teijin, Roche Bioscience, Sumitomo Pharmaceuticals, ImClone Systems, and Athena Neuroscience.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.